Cory Renauer is an Analyst at BioSpace. He specializes in investing in healthcare and fintech stocks, focusing on helping everyday investors navigate the complexities of the financial markets. Cory's insights and analyses have been featured in prominent outlets including Yahoo Finance, Nasdaq, and The Motley Fool.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Cory's articles primarily focus on investment analysis, with a particular emphasis on healthcare and pharmaceutical companies, as well as high-yield dividend stocks. He also covers stock market trends and specific stock recommendations based on data-driven analyses.
For effective outreach to Cory Renauer, consider providing data-backed insights into the performance of healthcare and pharmaceutical companies or high-yield dividend stocks. If you have expertise in analyzing investment opportunities within these sectors, particularly with reference to specific stocks or broader market trends, your pitch is likely to be well-received.
It's important that any information provided is backed by credible data and rigorous analysis given Cory's strong reliance on cited data in his coverage.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Cory Renauer
Kyndryl Holdings delivers IT infrastructure and cloud solutions to enterprise clients across diverse global industries.
This digital manufacturing platform, serving diverse industries, reported a notable insider sale amid strong one-year stock performance.
By: Cory Renauer
This global pumping systems provider operates across key infrastructure markets; a recent insider sale highlights evolving ownership trends.
By: Cory Renauer
Peloton, a leader in connected fitness and digital subscriptions, reported a notable insider sale amid ongoing market challenges.
By: Cory Renauer
This clinical-stage biotech focused on antibody therapies for immunological disorders reported a notable insider sale in its latest filing.
By: Cory Renauer
Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials.
Progyny delivers fertility benefits to major employers; a key insider recently trimmed their stake, according to SEC filings.
By: Cory Renauer
This clinical-stage biotech focused on rare diseases reported a notable insider sale amid a year of strong stock performance.
By: Cory Renauer
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.
By: Cory Renauer
This Bermuda-based bank with a strong dividend and island presence just reported a notable insider purchase in recent filings.
